What Is Parathyroid Hormone? The Peptide That Only Builds Bone If You Pulse It
Peptide biology
Parathyroid hormone is the body's calcium thermostat, and it is the clearest example in endocrinology of a peptide whose effect reverses depending on how long it lingers. Leave parathyroid hormone switched on and it takes bone apart. Deliver the identical molecule as a spike that has cleared by bedtime and it lays bone down — well enough that a 34-residue fragment of it became one of the first genuinely anabolic osteoporosis drugs. The variable is not the dose. It is the clock.
What parathyroid hormone actually is
Four small glands behind the thyroid make it. Their chief cells carry a calcium-sensing receptor (CASR) on the surface, cloned in 1993, that reads free calcium in the blood and throttles hormone release accordingly — the sensor and the effector sit in the same cell, which is why the system corrects so fast.
The molecule itself is built the way most peptide hormones are, by cutting a longer precursor down. Translation produces a 115-residue preproPTH; a 25-residue signal sequence comes off, then a six-residue propeptide, leaving the 84-residue mature hormone at about 9,425 daltons. If that precursor-to-hormone route looks familiar, it is the standard one.
What is not standard is how little of the finished hormone matters. Everything the receptor needs sits in the first 34 residues; the remaining fifty can be discarded without losing activity, a point established in the early 1970s and now sold in a syringe.
Three organs, one number
PTH exists to hold serum calcium steady, and it pulls three levers to do it.
- Kidney. It increases calcium reabsorption in the distal convoluted tubule and collecting duct, dumps phosphate at the proximal tubule, and switches on 1-alpha-hydroxylase, the enzyme that converts 25-hydroxyvitamin D into calcitriol.
- Gut. Indirectly, through that calcitriol, which is what actually drives intestinal calcium absorption. PTH never touches the intestine itself.
- Bone. The largest calcium reservoir in the body, and the one with the interesting behaviour.
All of this runs through PTH1R, a class B G-protein-coupled receptor expressed on osteoblasts, osteocytes and renal tubular cells, coupling to Gs and Gq and generating cAMP. Note what PTH does not do: it has no direct receptor on the osteoclast. Everything it achieves in bone is relayed through the osteoblast lineage.
Why the same hormone can build bone or destroy it
The relay through the osteoblast is the whole explanation. When PTH1R signalling is sustained, osteoblast-lineage cells raise RANKL and suppress osteoprotegerin, the decoy receptor that normally soaks RANKL up. The ratio tips, osteoclasts are recruited and live longer, and resorption wins. This is what a parathyroid adenoma does over years, and it shows up preferentially as cortical bone loss — the distal radius thins while the lumbar spine is relatively spared.
When the same signal is transient, a different set of consequences dominates, because several of the downstream effectors are short-lived:
- RUNX2, the master osteoblast transcription factor, is stabilised rather than shunted straight to the proteasome. The paper that showed this called it a putative explanation for why intermittent administration is needed for bone anabolism.
- Osteoblast apoptosis is suppressed via cAMP/PKA/CREB signalling, so the cells that build bone simply survive longer.
- Sclerostin (SOST), the osteocyte-derived brake on Wnt signalling, falls — and in mice whose osteocytes lack PTH1R, intermittent PTH neither suppresses sclerostin nor builds bone.
- Quiescent bone-lining cells are reactivated into working osteoblasts, adding bone at surfaces that were not remodelling at all.
This is close cousin to the general problem of what continuous receptor stimulation does to a signalling system, and it deserves an honest caveat: the field has not reduced the anabolic window to a single pathway. The most-cited review on the subject concludes flatly that there is no common intermittent-PTH pathway, and the contribution of the extra osteoclasts that intermittent dosing also recruits remains unclear. Pulse, do not pour — but the mechanism is a committee, not a switch.
Four drugs built on that one insight
The clearest evidence for the pulse-versus-flat principle is not an animal study. It is four prescribing labels, in which the same 34-residue fragment is engineered to opposite pharmacokinetic targets depending on what the prescriber wants.
Teriparatide is PTH(1–34), 4,118 daltons, with a subcutaneous half-life of about an hour; its label records serum calcium peaking four to six hours after a dose and no longer differing from placebo by sixteen hours. In the pivotal trial it cut new vertebral fractures from 14.3% to 5.0%.
Abaloparatide is a 34-residue analogue of PTHrP rather than PTH — 3,961 daltons, 76% homologous to human PTHrP(1–34) and only 41% to PTH(1–34) — and is thought to favour a shorter-lived receptor conformation, which is a conformational-selectivity argument rather than a potency one.
Palopegteriparatide is the mirror image of the design brief. It is a prodrug that slowly autocleaves to release exactly the same PTH(1–34), and its label states plainly that this gives continuous exposure across the entire 24-hour dosing period, with an apparent half-life near 60 hours. For hypoparathyroidism, the flat line is the therapeutic goal.
Full-length PTH(1–84) was also marketed for hypoparathyroidism, kept its osteosarcoma boxed warning and a restricted distribution programme throughout, and is gone: manufacturing ended in December 2024 after unresolved supply problems, and the US special-use programme closed at the end of 2025.
The osteosarcoma detour
Anyone reading about PTH drugs runs into a boxed warning that is no longer there, so it is worth stating what happened. Fisher rats dosed once daily for most of their lives developed dose-dependent osteosarcoma, at exposures the original warning described as three to sixty times the human 20-microgram dose. That finding cut the pivotal human trial short after a median of nineteen months and put a boxed warning on the drug.
Rats, however, grow bone continuously for life and lack the osteonal remodelling humans have. A second rat study at a clinically relevant dose produced no tumours; monkeys at eight times clinical exposure produced none. Fifteen years of postmarketing surveillance across roughly 2.47 million treated patients found three observed osteosarcoma cases against 4.17 expected — a standardised incidence ratio of 0.72. The boxed warning came off in November 2020; the warning itself stayed in the body of the label, as did the advice not to exceed two years without a good reason. Abaloparatide's boxed warning was removed the following year, but its flat two-year lifetime limit remains in force — a distinction that is easy to get wrong.
When the system breaks
- Primary hyperparathyroidism — usually a single adenoma. High PTH, high calcium, low phosphate, and the cortical bone loss described above.
- Secondary hyperparathyroidism — the gland responding appropriately to chronic kidney disease. High PTH with low calcium and high phosphate, the opposite pattern.
- Hypoparathyroidism — most often a consequence of neck surgery, and the indication that both PTH replacement products were built for.
- Humoral hypercalcaemia of malignancy — driven by PTHrP, a separate gene product circulating as isoforms of 139, 141 or 173 residues, sharing eight of PTH's first thirteen residues and therefore the same receptor.
Cinacalcet approaches the same axis from the sensor end: it is a calcimimetic that makes CASR more sensitive to ambient calcium, so the gland behaves as though calcium were higher than it is and releases less hormone. That is allosteric modulation rather than blockade.
Why the PTH number on a lab report is slippery
PTH assays are a cautionary tale about measuring peptides. Second-generation "intact PTH" sandwich assays use an N-terminal antibody that does not reach the first four residues, so they also count C-terminal fragments — chiefly PTH(7–84) — which accumulate in kidney disease and do not activate PTH1R. Different manufacturers aim their antibody at different epitopes, so two hospitals running the same generation of assay can return different numbers on the same sample. PTH can also be oxidised at methionines 8 and 18, particularly in renal disease, which abolishes receptor activation but not immunoreactivity. The assay sees a hormone that the receptor does not.
Frequently asked questions
Is PTH a steroid or a peptide?
A peptide — 84 amino acids, water-soluble, acting on a cell-surface receptor rather than entering the nucleus. That places it firmly in the peptide hormone class alongside insulin and glucagon.
Why does teriparatide have to be injected daily rather than weekly?
Because the anabolic effect depends on the exposure returning to baseline between doses. Stretch the interval and you lose pulses; flatten the curve and you lose the anabolic effect entirely. The dosing interval is doing pharmacological work, not just convenience.
What is the difference between PTH(1–34) and PTH(1–84)?
Chemically, fifty residues. Functionally, almost nothing at the receptor — but the shorter fragment clears faster, which is precisely why it is the one used to build bone. The pharmacokinetics are the therapy.
Why do so many peptide drug names end in "-tide"?
Because the stem is assigned by international nomenclature rules, not marketing. Teriparatide, abaloparatide and palopegteriparatide all carry it; the naming system has its own logic.
References
- Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates. JBMR Plus 2022;6(9):e10665. academic.oup.com
- Osagie-Clouard L, Sanghani A, Coathup M, et al. Parathyroid hormone 1-34 and skeletal anabolic action. Bone Joint Res 2017;6(1):14–21. boneandjoint.org.uk
- Gardella TJ, Vilardaga JP. International Union of Basic and Clinical Pharmacology. XCIII. The Parathyroid Hormone Receptors. Pharmacol Rev 2015;67(2):310–337. PMC4394688
- FORTEO (teriparatide injection) prescribing information. DailyMed, US National Library of Medicine. dailymed.nlm.nih.gov
- YORVIPATH (palopegteriparatide) injection prescribing information. DailyMed, US National Library of Medicine. dailymed.nlm.nih.gov
- UniProtKB P01270 — Parathyroid hormone, Homo sapiens. uniprot.org
Informational only — not medical advice. This article describes published research and regulatory documents and is not guidance for personal use. Consult a qualified healthcare professional about diagnosis or treatment. Intended for readers 21+.